These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Hubbard R; Venn A; Smith C; Cooper M; Johnston I; Britton J Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):743-7. PubMed ID: 9517585 [TBL] [Abstract][Full Text] [Related]
27. The morphogenesis and classification of diffuse interstitial lung diseases: a clinicopathological approach, based on tissue reaction patterns. Henderson DW Aust N Z J Med; 1984 Oct; 14(5 Suppl 3):735-48. PubMed ID: 6598040 [TBL] [Abstract][Full Text] [Related]
28. Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis. Reghellin D; Poletti V; Tomassett S; Dubini A; Cavazza A; Rossi G; Lestani M; Pedron S; Daniele I; Montagna L; Murer B; Chilos M Sarcoidosis Vasc Diffuse Lung Dis; 2010 Jul; 27(1):57-63. PubMed ID: 21086906 [TBL] [Abstract][Full Text] [Related]
30. Up-regulation of IL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis. Pantelidis P; Southcott AM; Black CM; Du Bois RM Clin Exp Immunol; 1997 Apr; 108(1):95-104. PubMed ID: 9097917 [TBL] [Abstract][Full Text] [Related]
31. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Rossi GA; Bitterman PB; Rennard SI; Ferrans VJ; Crystal RG Am Rev Respir Dis; 1985 Apr; 131(4):612-7. PubMed ID: 3994157 [TBL] [Abstract][Full Text] [Related]
32. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. McCormick LL; Zhang Y; Tootell E; Gilliam AC J Immunol; 1999 Nov; 163(10):5693-9. PubMed ID: 10553100 [TBL] [Abstract][Full Text] [Related]
33. [The potential role of cytokines expression in idiopathic pulmonary fibrosis]. Guo Z; Cao B; Zhu Y; Xu W Zhonghua Jie He He Hu Xi Za Zhi; 1999 Jan; 22(1):33-6. PubMed ID: 11812353 [TBL] [Abstract][Full Text] [Related]
34. Proliferative activity in fibrosing lung diseases: a comparative study of Ki-67 immunoreactivity in diffuse alveolar damage, bronchiolitis obliterans-organizing pneumonia, and usual interstitial pneumonia. El-Zammar O; Rosenbaum P; Katzenstein AL Hum Pathol; 2009 Aug; 40(8):1182-8. PubMed ID: 19368952 [TBL] [Abstract][Full Text] [Related]
35. Alveolar macrophage lysosomal enzyme and C3b receptors in cryptogenic fibrosing alveolitis. du Bois RM; Townsend PJ; Cole PJ Clin Exp Immunol; 1980 Apr; 40(1):60-5. PubMed ID: 7389217 [TBL] [Abstract][Full Text] [Related]
36. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Imokawa S; Sato A; Hayakawa H; Kotani M; Urano T; Takada A Am J Respir Crit Care Med; 1997 Aug; 156(2 Pt 1):631-6. PubMed ID: 9279250 [TBL] [Abstract][Full Text] [Related]
37. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Wells AU; Hansell DM; Haslam PL; Rubens MB; Cailes J; Black CM; du Bois RM Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1474-82. PubMed ID: 9603126 [TBL] [Abstract][Full Text] [Related]